BIOCON LTD. - 532523 - Shareholder Meeting - AGM On 11/08/2023
Notice of 45th Annual General Meeting and Integrated Annual Report for the FY 2022-2320-07-2023
20-07-2023
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copies of newspaper advertisement published on July 18, 2023 in Financial Express (English Language) and Vijayavani (Kannada Language) intimating that 45th Annual General Meeting of the Company will be held on Friday, August 11, 2023 at 3:30 pm (IST) through Video Conferencing/Other Audio Visual Means.18-07-2023
BIOCON LTD. - 532523 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5)of SEBI (Depositories and Participants) Regulations, 2018 during the quarter ended June 30, 2023.12-07-2023
BIOCON LTD. - 532523 - Communication To The Shareholders W.R.T. TDS On Final Dividend
Pursuant to the declaration of final dividend by the Board of Directors of the Company at its Board Meeting held on May 23, 2023, the Company has sent the enclosed email communication to its shareholders, with respect to the deduction of tax at source on Final Dividend for the Financial Year 2022-23, whose email addresses are registered with the Company/Depository Participants.10-07-2023
Biocon Biologics ahead of plan in integrating Viatris'
The biosimilar unit of Biocon expects to raise additional capital this year, says CEO Tambe06-07-2023
BIOCON LTD. - 532523 - Intimation Under Regulation 30 (6) Of SEBI Listing Obligations And Disclosure Requirements (LODR) Regulations, 2015.
Meeting conducted with Institutional Investors/Research Analysts.06-07-2023
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release titled "Biocon Biologics expands Footprint in emerging markets; Takes over the commercialization of Biosimilars Business from Viatris in 70+ countires."05-07-2023
Biosimilar Humira likely to boost US revenues for Biocon Biologics
Analysts, however, feel that together with upcoming Aspart (insulin) and vaccines, Hulio will help drive BBL's revenues from the current $1 billion to around $1.65 billion by FY2504-07-2023
BIOCON LTD. - 532523 - Intimation Under Regulation 30 (6) Of SEBI Listing Obligations And Disclosure Requirements (LODR) Regulations, 2015.
Meeting conducted with Institutional Investors/Research Analysts.04-07-2023
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release03-07-2023